Free Trial

Galera Therapeutics (GRTX) SEC Filings & 10K Form

$0.19
-0.01 (-5.09%)
(As of 05/20/2024 ET)

Recent Galera Therapeutics SEC Filings

DateFilerForm TypeView
05/16/2024
9:25 AM
Galera Therapeutics (Subject)
Soffer Rochel (Filed by)
Form SC 13G
05/16/2024
9:26 AM
Galera Therapeutics (Subject)
Schneid Yair (Filed by)
Form SC 13G/A
05/16/2024
9:26 AM
ALPHA PHARMA Investments LLC (Reporting)
Galera Therapeutics (Issuer)
Soffer Rochel (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/13/2024
6:30 AM
Galera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2024
6:05 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/03/2024
3:07 PM
Galera Therapeutics (Filer)
Form 8-A12B
05/01/2024
4:02 PM
Galera Therapeutics (Issuer)
Schneid Yair (Reporting)
Form 4/A
04/16/2024
3:39 PM
ALPHA PHARMA Investments LLC (Filed by)
Galera Therapeutics (Subject)
Form SC 13G
04/03/2024
7:08 AM
Altamont Pharmaceutical Holdings, LLC (Filed by)
Galera Therapeutics (Subject)
Form SC 13G/A
04/01/2024
8:36 PM
Altamont Pharmaceutical Holdings, LLC (Reporting)
Galera Therapeutics (Issuer)
Pearson Mark E. (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
03/28/2024
6:30 AM
Galera Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/28/2024
6:06 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2024
6:31 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2024
5:57 PM
Galera Therapeutics (Subject)
Sofinnova Venture Partners IX, L.P. (Filed by)
Form SC 13D/A
01/16/2024
5:11 PM
Galera Therapeutics (Issuer)
Schneid Yair (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/02/2024
7:35 AM
Galera Therapeutics (Subject)
GSA CAPITAL PARTNERS LLP (Filed by)
Form SC 13G
12/04/2023
3:32 PM
Blackstone Holdings I/II GP L.L.C. (Filed by)
Galera Therapeutics (Subject)
Form SC 13D/A
11/13/2023
1:22 PM
Altamont Pharmaceutical Holdings, LLC (Reporting)
Galera Therapeutics (Issuer)
Pearson Mark E. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/13/2023
1:24 PM
Altamont Pharmaceutical Holdings, LLC (Filed by)
Galera Therapeutics (Subject)
Form SC 13G
10/31/2023
6:10 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2023
6:24 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/22/2023
4:12 PM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2023
6:30 AM
Galera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2023
6:30 AM
Galera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2023
6:10 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/10/2023
7:00 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/05/2023
3:19 PM
Alleva Lawrence M (Reporting)
Galera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2023
3:19 PM
Galera Therapeutics (Subject)
Novo Holdings A/S (Filed by)
Form SC 13G/A
06/15/2023
3:12 PM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/30/2023
7:51 AM
Galera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:GRTX) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners